Expands Services, Offers Absolute Sample Protection
(Seattle, Wash.; Feb. 3, 2016) - LabConnect, a leading provider of highly customized global central laboratory services to biopharmaceutical, medical device and contract research organizations, has built a new biorepository facility to expand services and better meet the evolving needs of the industry.
LabConnect’s new, 5,000-square-foot biorepository in Johnson City, Tenn., features space for ambient, refrigerated, cold (-20C) and ultra-low temperature (-70C to -80C) storage as well as liquid nitrogen vapor phase storage (-190C).
“Proper sample management is essential to both today’s and tomorrow’s clinical trials,” said Eric Hayashi, LabConnect president and CEO. “Researchers depend on the integrity and availability of their stored biospecimens to retest them to verify trends or unexpected results, or for later retrieval to support specific biomarker research.”
With storage capacity for more than 8 million samples, LabConnect ensures the integrity of samples as well as business continuity with fully validated and mapped backup freezers and generators, redundant HVAC systems, whole building and biorepository security systems and a temperature monitoring system for all freezers and refrigerators with a 21 CFR Part 11 compliant audit trail.
“There are many biorepositories, but LabConnect’s facility is truly state-of-the art, using the most advanced technology available to provide the best protection in the industry for biospecimens,” said George Lewis, senior engineering technician at Johnson Controls, which supplies equipment to the Johnson City facility.
Additionally, through its SampleGISTICS™ system, LabConnect tracks sample locations and consolidates data within a centralized database accessible to researchers 24/7.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.